1 |
Almutairi AO, El-Readi MZ, Althubiti M, Alhindi YZ, Ayoub N, Alzahrani AR, Al-Ghamdi SS, Eid SY. Liver Injury in Favipiravir-Treated COVID-19 Patients: Retrospective Single-Center Cohort Study. Trop Med Infect Dis 2023;8. [PMID: 36828545 DOI: 10.3390/tropicalmed8020129] [Reference Citation Analysis]
|
2 |
Li X, Wang W, Yan S, Zhao W, Xiong H, Bao C, Chen J, Yue Y, Su Y, Zhang C. Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1019487] [Reference Citation Analysis]
|
3 |
Pop C, Pop M. Should Patients With COVID-19 Receive Post-Discharge Thromboprophylaxis? Short Answers to Frequently Asked Questions. Romanian Journal of Cardiology 2022;0. [DOI: 10.2478/rjc-2022-0026] [Reference Citation Analysis]
|
4 |
Goldust M. Coronavirus Disease 2019 (COVID-19). Biology 2022;11:1250. [DOI: 10.3390/biology11081250] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
Negru PA, Radu AF, Vesa CM, Behl T, Abdel-Daim MM, Nechifor AC, Endres L, Stoicescu M, Pasca B, Tit DM, Bungau SG. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir. Biomed Pharmacother 2022;147:112700. [PMID: 35131656 DOI: 10.1016/j.biopha.2022.112700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|